Drug
Bemcentinib clinical trials
Also written BGB324.
- studies test it
- 11
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
11 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 5
- Phase 2
- 8
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 6
BerGenBio ASA (5) · University of Leicester (1) · Haukeland University Hospital (1) · University of Texas Southwestern Medical Center (1) · GWT-TUD GmbH (1) · The University of Texas Health Science Center at San Antonio (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
Often tested with
Tested in the same studies.
Pembrolizumab (5) · Rucaparib (1) · Abemaciclib (1) · Atezolizumab (1) · Bevacizumab (1) · Dostarlimab (1) · Niraparib (1) · Dabrafenib (1)
Studies
Open first, then newest update. How each study uses bemcentinib is read from its arms, and is right about nine times in ten.
Testing it · 11
- Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaCompletedPhase 2University of LeicesterNCT03654833Written as pembrolizumab & bemcentinib
- Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung AdenocarcinomaTerminatedPhase 1/2The University of Texas Health Science Center at San AntonioNCT06516887Written as bemcentinib
- A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 GeneTerminatedPhase 1/2BerGenBio ASANCT05469178Written as Bemcentinib
- Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedPhase 2BerGenBio ASANCT03184571Written as Bemcentinib
- A Study to Investigate 14C-bemcentinib in Healthy Male SubjectsCompletedPhase 1BerGenBio ASANCT06469138Written as Bemcentinib
- BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic MelanomaCompletedPhase 1/2Haukeland University HospitalNCT02872259Written as BGB324+pembrolizumab
- A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised PatientsCompletedPhase 2BerGenBio ASANCT04890509Written as Bemcentinib
- Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.CompletedPhase 1University of Texas Southwestern Medical CenterNCT02922777Written as BGB324
- AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing SurgeryTerminatedEarly Phase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03965494Written as BGB 324 (before surgery)
- Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic SyndromesCompletedPhase 2GWT-TUD GmbHNCT03824080Written as Bemcentinib
- Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBCTerminatedPhase 2BerGenBio ASANCT03184558Written as Bemcentinib; pembrolizumab
Given in every arm · 4 — bemcentinib is usual care beside what is tested
- Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell CarcinomaRecruitingPhase 3Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityNCT07445048Written as Bemcentinib
- A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung CancerCompletedPhase 1/2BerGenBio ASANCT02424617Written as Bemcentinib
- A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDSCompletedPhase 1/2BerGenBio ASANCT02488408Written as Bemcentinib
- Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic CancerTerminatedPhase 1/2University of Texas Southwestern Medical CenterNCT03649321Written as Bemcentinib
Codes
What other systems call bemcentinib · ClinicalTrials.gg INT005597
- MeSH (NLM) C548378bemcentinibOne source NLM
- UNII (FDA) 0ICW2LX8ASBEMCENTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27236818bemcentinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C121854BemcentinibOne source FDA
- DrugBank DB12411One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C548378 | bemcentinib | One source NLM |
| UNII (FDA) | 0ICW2LX8AS | BEMCENTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27236818 | bemcentinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C121854 | Bemcentinib | One source FDA |
| DrugBank | DB12411 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.